Kimberly A Kaphingst, Wendy K Kohlmann, Rachelle Lorenz Chambers, Jemar R Bather, Melody S Goodman, Richard L Bradshaw, Daniel Chavez-Yenter, Sarah V Colonna, Whitney F Espinel, Jessica N Everett, Michael Flynn, Amanda Gammon, Adrian Harris, Rachel Hess, Lauren Kaiser-Jackson, Sang Lee, Rachel Monahan, Joshua D Schiffman, Molly Volkmar, David W Wetter, Lingzi Zhong, Devin M Mann, Ophira Ginsburg, Meenakshi Sigireddi, Kensaku Kawamoto, Guilherme Del Fiol, Saundra S Buys
IMPORTANCE: Increasing numbers of unaffected individuals could benefit from genetic evaluation for inherited cancer susceptibility. Automated conversational agents (ie, chatbots) are being developed for cancer genetics contexts; however, randomized comparisons with standard of care (SOC) are needed. OBJECTIVE: To examine whether chatbot and SOC approaches are equivalent in completion of pretest cancer genetic services and genetic testing. DESIGN, SETTING, AND PARTICIPANTS: This equivalence trial (Broadening the Reach, Impact, and Delivery of Genetic Services [BRIDGE] randomized clinical trial) was conducted between August 15, 2020, and August 31, 2023, at 2 US health care systems (University of Utah Health and NYU Langone Health)...
September 3, 2024: JAMA Network Open